logo
LIBOGENE is in the business of cancer molecular diagnosis. The company has established an internationally certified CAP laboratory, and is building a tumor mutant gene databank. LIBOGENE has successfully developed many targeted cancer treatment testing panels and identified novel indigenous tumor resistant gene mutations which can be used as important diagnostic biomarkers.
If you have any questions about our products and services, please input the following details, we will contact you as soon as possible to answer your questions.

繁中  |  简中  |  ENG

Understanding the tumor targeted drug companion diagnosis in 3 minutes

Traditional cancer treatments include surgery, radiation therapy and chemical therapy. The former two are localized therapies. When cancer cells metastasize, chemical therapy must be used for overall treatment. However, chemical therapy often has severe side effects that are difficult for patients to deal with and some even give up treatment.

Since the first target drug Imatinib became available in 2000, cancer therapy became significantly related to individual genotypes. Target drugs must be administered according to the patient’s cancer cell genetic traits. The American FDA recommends that before targeted drugs are administered, corresponding biomarker tests should be conducted to ensure the effectiveness and safety of the treatment. Thus, a personalized drug requirement demand has been created. This is also the advent of the personalized medical care age.

See More

LIBOGENE, The leading brand of precision medicine

LIBOGENE is in the business of cancer molecular diagnosis. The company has established an internationally certified CAP laboratory, and is building a tumor mutant gene databank. LIBOGENE has successfully developed many targeted cancer treatment testing panels and identified novel indigenous tumor resistant gene mutations which can be used as important diagnostic biomarkers.

The vision of LIBOGENE is to use the Ion Torrent system developed by the Thermo Fisher (formerly Life) company as the platform and develop various companion diagnostic test panels for targeted cancer drugs. This can accurately identify the genetic abnormalities, while making the service affordable. The service can be expanded to the gene mutations that are the focus of first to third phase target drug clinical trials. LIBOGENE hopes to become a leading clinical testing company. The company is also developing a large database and moving towards new drug development.

See All Certificates

LIBOGENE, The leading brand of precision medicine

LIBOGENE is in the business of cancer molecular diagnosis. The company has established an internationally certified CAP laboratory, and is building a tumor mutant gene databank. LIBOGENE has successfully developed many targeted cancer treatment testing panels and identified novel indigenous tumor resistant gene mutations which can be used as important diagnostic biomarkers.

The vision of LIBOGENE is to use the Ion Torrent system developed by the Thermo Fisher (formerly Life) company as the platform and develop various companion diagnostic test panels for targeted cancer drugs. This can accurately identify the genetic abnormalities, while making the service affordable. The service can be expanded to the gene mutations that are the focus of first to third phase target drug clinical trials. LIBOGENE hopes to become a leading clinical testing company. The company is also developing a large database and moving towards new drug development.

See All Certificates

Our Services

Non-small cell lung cancer gene detection panel

The non-small cell lung cancer gene detection panel detects 16 genes and 75 mutation sites, including specific gene mutations that code for the targets for targeted therapies and tumor resistant gene mutations which can be used as important diagnostic biomarkers. We aim to help physicians identify the right drugs so that treatment effect could be maximized while reducing unwanted treatment-induced side effects.

Details

Colorectal cancer gene detection panel

The colorectal cancer gene detection panel detects 8 genes and 79 mutation sites, including specific gene mutations that code for the targets for targeted therapies and tumor resistant gene mutations which can be used as important diagnostic biomarkers. We aim to help physicians identify the right drugs so that treatment effect could be maximized while reducing unwanted treatment-induced side effects.

Details

Comprehensive cancer gene detection panel

The comprehensive cancer gene detection panel detects 30 genes and 280 mutation sites, including specific gene mutations that code for the targets for targeted therapies and tumor resistant gene mutations which can be used as important diagnostic biomarkers. We aim to help physicians identify the right drugs so that treatment effect could be maximized while reducing unwanted treatment-induced side effects.

Details

Our Core Value

Transform cancer care-together, we care  

Each test report is personally reviewed and approved by a pathologist. LIBOGENE treat each test report with the utmost caution, and provides patients and doctors with the most accurate test report.

麗寶生醫所創立的麗寶基因LIBOGENE提供基因檢測服務不僅位點精準且高CP值,並且每一份檢測報告均有病理醫生親簽核對,針對每一份檢測報告,麗寶基因LIBOGENE秉持著最嚴謹的態度,提供客戶與醫生最準確的檢測數據。

Our Features

Global authorities on cancer

Libogene collaborated with global authorities on cancer to provide you with the most complete testing experience

Pathology accreditation

The world’s highest standard of pathology accreditation.

CAP accreditation

The first company in the world to received CAP accreditation.

The first company

The first company in the world to extend the use of second generation sequencing from research purposes to cancer testing.

International clinical trial

International clinical trial recognition study.

Thermo Fisher-certified

The world’s first Thermo Fisher Scientific-certified Ion Torrent service provider.

Renowned doctors on cancer gene testing

For many years, the medical and science communities have explored the causes of cancer and its treatment method. Many studies have proven that cancer is a disease caused by gene mutation.Gene mutation occurs for two reasons:
1. Innate genetic inheritance
2. Environment, living habits and long-term exposure to carcinogens

In the new “specific patient, specific symptom” medical age, genetic testing can be used for gene abnormality analysis of gene clusters targeted by cancer drugs for newly diagnosed cancer patients or cancer recurrence patients (by using extracted cancer cell DNA from surgically removed specimens or tumor biopsy). When the doctor is making a diagnosis and he/she has the patient’s cancer cell gene mutation information, the doctor can use this information to choose the most appropriate targeted drug. This avoids the use of ineffective treatment and makes the best use of crucial treatment time. As a result, treatment effectiveness and the patient’s life quality can increase significantly.

See All Services

Precision treatment with genetic testing

The LIBOGENE genetic testing services are not only accurate, but economical. Each test report is personally reviewed and approved by a pathologist

Dr. Chou, Teh-Ying


Director of the Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital

Present position
– Director of the Taiwan Society of Pathology
– Dean and Professor of the Institute of Clinical Medicine, National Yang-Ming University

Dr. Chen, Rong-Long


Pediatric oncology doctor at the Koo Foundation Sun Yat-Sen Cancer Center

Present position
– Attending physician in the Pediatric Hematology and Oncology Department at the Koo Foundation Sun Yat-Sen Cancer Center

Dr. Tsai, Chun-Ming


Former director of the Department of Thoracic Oncology, Taipei Veterans General Hospital

Present position
-Special attending physician in the thoracic department at the Taipei Veterans General Hospital

Dr. Ku, Wen-Hui


Director of the Department of Clinical Pathology and Molecular Medicine , Taipei Institute of Pathology

Present position
-Director of the Department of Clinical Pathology, Taipei Institute of Pathology
-Director of the Department of Molecular Medicine, Taipei